Abstract:Objective: Hepatocellular carcinoma (HCC) is a highly heterogeneous disease with a dismal prognosis. However, driver genes and prognostic markers in HCC remain to be identified. It is hoped that in-depth analysis of HCC genomes in relation to available clinicopathological information will give rise to novel molecular prognostic markers. Methods: We collected genomic data of 1,061 HCC patients from previous studies, and performed integrative analysis to identify significantly mutated genes and molecular prognosticators. We employed three MutSig algorithms (MutSigCV, MutSigCL and MutSigFN) to identify significantly mutated genes. The GISTIC2 algorithm was used to delineate focally amplified and deleted genomic regions. Nonnegative matrix factorization (NMF) was utilized to decipher mutational signatures. Kaplan-Meier survival and Cox regression analyses were used to associate gene mutation and copy number alteration with survival outcome. Logistic regression model was applied to test association between gene mutation and mutational signatures. Results: We discovered 11 novel driver genes, including RNF213, VAV3 and TNRC6B, with mutational prevalence ranging from 1% to 3%. Seven mutational signatures were also identified in HCC, some of which were associated with mutations of classical driver genes (e.g., TPS3, TERT) as well as alcohol consumption. Focal amplifications of TERT and other druggable targets, including AURKA, were also revealed. Targeting AURKA by a small-molecule inhibitor potently induced apoptosis in HCC cells. We further demonstrated that HCC patients with TERT amplification displayed shortened overall survival independent of other clinicopathological parameters. In conclusion, our study identified novel cancer driver genes and prognostic markers in HCC, reiterating the translational importance of omics data in the precision medicine era.

Precision Medicine for Hepatocellular Carcinoma: Driver Mutations and Targeted Therapy

Emerging Biomolecules for Practical Theranostics of Liver Hepatocellular Carcinoma.

Molecular Subtyping of Hepatocellular Carcinoma: A Step Toward Precision Medicine

Interactions Between Driver Genes Shape the Signaling Pathway Landscape and Direct Hepatocellular Carcinoma Therapy

Emerging Role of Molecular Diagnosis and Personalized Therapy for Hepatocellular Carcinoma

Tumor-Associated Neutrophils: an Emerging Player in the Immune Microenvironment of Hepatocellular Carcinoma

Genomic analysis of liver cancer unveils novel driver genes and distinct prognostic features.

Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective

Advances of Targeted Therapy for Hepatocellular Carcinoma

Precision Targeting in Hepatocellular Carcinoma: Exploring Ligand-Receptor Mediated Nanotherapy.

TP53 and RET May Serve As Biomarkers of Prognostic Evaluation and Targeted Therapy in Hepatocellular Carcinoma.

Precision models in hepatocellular carcinoma

The advanced development of molecular targeted therapy for hepatocellular carcinoma

Molecular Diagnosis and Therapy of Hepatocellular Carcinoma: Achievements and Challenges

Early Diagnosis and Therapeutic Strategies for Hepatocellular Carcinoma: from Bench to Bedside

Research Advances in Systemic Therapy for Hepatocellular Carcinoma in the Era of Precision Medicine

Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma

Immunotherapy, targeted therapy, and their cross talks in hepatocellular carcinoma

Targeted Drug Delivery Strategies for the Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets

Precision Diagnosis and Treatment of Liver Cancer in China.